{
    "clinical_study": {
        "@rank": "141238", 
        "acronym": "ENDOMAX", 
        "arm_group": [
            {
                "arm_group_label": "Bivalirudin", 
                "arm_group_type": "Experimental", 
                "description": "Bivalirudin will be administered as a bolus and infusion. The bolus (0.75 mg/kg) will be administered via systemic IV administration.  Immediately after the bolus, an IV infusion of bivalirudin will be initiated at a dose of 1.75 mg/kg/h (or 1 mg/kg/h for subjects with an eGFR <30 mL/min)."
            }, 
            {
                "arm_group_label": "Heparin", 
                "arm_group_type": "Active Comparator", 
                "description": "UFH will be administered as an initial weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg.  Additional bolus doses may be administered per the pre-defined heparin dosing algorithm."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to demonstrate that anticoagulation with bivalirudin\n      results in fewer major bleeding complications compared with unfractionated heparin (UFH) in\n      subjects undergoing peripheral endovascular interventions (PEI). The secondary objective is\n      to identify potential benefits from bivalirudin therapy on other clinically important events\n      such as death, myocardial infarction (MI), stroke and/or transient ischemic attack (TIA),\n      amputation, unplanned repeat revascularization (URV), and minor bleeding, as well as\n      potential economic benefits that may result from improved clinical outcomes."
        }, 
        "brief_title": "ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial", 
        "condition": "Peripheral Endovascular Interventions", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects \u2265 18 years of age\n\n          -  Must be undergoing one of the following PEI procedures:\n\n               -  Carotid artery stenting (approximately 33% of study sample)\n\n               -  Lower Extremity Interventions (LEI) for Critical Limb Ischemia (CLI)\n                  (approximately 33% of study sample)\n\n               -  LEI for claudication (approximately 33% of study sample)\n\n          -  Provide written informed consent prior to any study-specific procedure being\n             performed\n\n        Exclusion Criteria:\n\n          -  Any known contra-indication to the use of bivalirudin or UFH\n\n          -  Acute limb ischemia\n\n          -  Planned amputation regardless of the outcome of the PEI\n\n          -  Dialysis dependent\n\n          -  Weight less than 38 kilograms (kg) or more than 202 kg\n\n          -  History of any bleeding diathesis or severe hematological disease\n\n          -  History of intra-cranial: mass, aneurysm, arteriovenous malformation or hemorrhage\n\n          -  Gastrointestinal or genitourinary bleeding within the 30 days prior to randomization\n\n          -  Any surgery (including biopsy) within the 30 days prior to randomization\n\n          -  Concomitant percutaneous coronary intervention (PCI)\n\n          -  Any percutaneous coronary, endovascular, or structural heart disease procedure within\n             30 days prior to randomization\n\n          -  International normalized ratio (INR) >1.7 within 24 hours (h) prior to the index\n             procedure\n\n          -  Administration of therapeutic doses of UFH within 30 min prior to the index procedure\n             (a low dose [\u22642000 units (U)] of  heparin is permitted during the diagnostic\n             angiogram prior to the intervention)\n\n          -  Administration of enoxaparin within 8 hours; other low molecular weight heparins\n             (LMWHs) or fondaparinux within 24 hours; any oral anti-Xa or antithrombin agent\n             within 48 hours; or thrombolytics, glycoprotein inhibitors (GPI) or warfarin within\n             72 hours prior to the index procedure\n\n          -  Severe contrast allergy that cannot be pre-medicated\n\n          -  Procedures performed by radial access\n\n          -  Known or suspected pregnant women or nursing mothers\n\n          -  Previous enrollment in this study (MDCO-BIV-12-03)\n\n          -  Participation in other investigational drug or device trials within 30 days prior to\n             randomization, with the exception of ongoing participation in the EUCLID Trial which\n             is permitted\n\n          -  Subjects who, for any reason, are deemed by the investigator to be inappropriate for\n             this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "3900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913483", 
            "org_study_id": "MDCO-BIV-12-03"
        }, 
        "intervention": {
            "arm_group_label": [
                "Bivalirudin", 
                "Heparin"
            ], 
            "intervention_name": "Bivalirudin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bivalirudin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "CTheart0469@aol.com", 
                    "last_name": "Cyndi Tauth", 
                    "phone": "501-625-3400"
                }, 
                "facility": {
                    "address": {
                        "city": "Hot Springs", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "71901"
                    }, 
                    "name": "Tri-Lakes Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "CameronM@cccheart.com", 
                    "last_name": "Michele Cameron", 
                    "phone": "727-449-9257"
                }, 
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33756"
                    }, 
                    "name": "Clearwater Cardiovascular and Interventional Consultants"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kurtm@flrnetwork.com", 
                    "last_name": "Kurt Malphurs, Pharmacist", 
                    "phone": "352-333-0939"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32605"
                    }, 
                    "name": "Florida Research Network"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "parkh@mcrfmd.com", 
                    "last_name": "Holly Park", 
                    "phone": "563-324-4384"
                }, 
                "contact_backup": {
                    "email": "shammasg@mcrfmd.com", 
                    "last_name": "Gail Shammas", 
                    "phone": "563-324-4384"
                }, 
                "facility": {
                    "address": {
                        "city": "Davenport", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52803"
                    }, 
                    "name": "Midwest Cardiovascular Research Foundation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lediehl@novanthealth.org", 
                    "last_name": "Lance E. Diehl, MD", 
                    "phone": "704-264-1400"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28204"
                    }, 
                    "name": "Novant Health Heart and Vascular Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "muhammad.arida@conehealth.com", 
                    "last_name": "Muhammad Arida, MD", 
                    "phone": "336-832-3799"
                }, 
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27401"
                    }, 
                    "name": "LeBauer Cardiovascular Research Foundation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kathy.betsill@anmedhealth.org", 
                    "last_name": "Kathy Betsill, MS, RN, CNS", 
                    "phone": "864-512-8734"
                }, 
                "facility": {
                    "address": {
                        "city": "Anderson", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29621"
                    }, 
                    "name": "AnMed Health"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial", 
        "overall_contact": {
            "email": "tara.richardson@themedco.com", 
            "last_name": "Tara G Richardson", 
            "phone": "9732906103"
        }, 
        "overall_contact_backup": {
            "email": "jenna.bisch@themedco.com", 
            "last_name": "Jenna Bisch", 
            "phone": "9732906171"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Bleeding defined as Bleeding Academic Research Consortium (BARC) \u22653 within 48 hours post study drug initiation or at hospital discharge, whichever occurs first, as adjudicated by the CEC", 
            "measure": "Bleeding", 
            "safety_issue": "No", 
            "time_frame": "48 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "The Medicines Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Medicines Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}